1. Rocket Pharmaceuticals is under investigation for possible fiduciary breaches. 2. Insiders allegedly misled shareholders about RP-A501 trial safety and efficacy. 3. Serious adverse events, including patient deaths, were not disclosed adequately. 4. Trial protocol changes were made without informing investors promptly. 5. Shareholders who bought before February 27, 2025, are encouraged to contact legal firm.
The ongoing investigation and allegations may severely undermine investor confidence and trust, reminiscent of other biotech stocks facing litigation, typically leading to sharp declines in share prices.
The nature of the allegations directly affects the fiduciary integrity of Rocket Pharmaceuticals, which could lead to significant price drops in response to investor and market sentiment.
Legal investigations often lead to immediate stock volatility as investors react to the news; historical precedents show significant price drops occur in such scenarios.
NEW YORK, Sept. 19, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) breached their fiduciary duties to shareholders.
According to a federal securities lawsuit, Insiders at Rocket Pharmaceuticals caused the company to provide investors with material information concerning Rocket's Phase 2 pivotal trial of RP-A501 for the treatment of Danon disease. The statements included, among other things, confidence in the drug's safety and efficacy, as well as the clinical trial's detailed protocol and Rocket's purported ability to meet the trial's endpoints as per the Company's ascribed timeline. While, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of RPA501's safety and clinical trial protocol; notably, that Rocket knew Serious Adverse Events (SAEs), including death of participants enrolled in the study, were a risk. In particular, Rocket amended the trial's protocol to introduce a novel immunomodulatory agent to the pretreatment regimen without providing this critical update to shareholders.
If you currently own RCKT and purchased prior to February 27, 2025 please contact Justin Kuehn, Esq. here, by email at justin@kuehn.law or call (833) 672-0814. Kuehn Law pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
Why Your Participation Matters:
As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™
For additional information, please visit Shareholder Derivative Litigation - Kuehn Law.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts:
Kuehn Law, PLLC
Justin Kuehn, Esq.
53 Hill Street, Suite 605
Southampton, NY 11968
justin@kuehn.law
(833) 672-0814
View original content to download multimedia:https://www.prnewswire.com/news-releases/kuehn-law-encourages-investors-of-rocket-pharmaceuticals-inc-to-contact-law-firm-302561661.html
SOURCE Kuehn Law, PLLC